CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication

作     者：Tsung-Jung Lin Hsi-Chang Lee Chih-Lin Lin Chung-Kwe Wang Kuan-Yang Chen Deng-Chyang Wu 

作者机构：Department of Health care and Social WorkTaipei University of Marine Technology Department of GastroenterologyTaipei City Hospital Institute of Clinical MedicineNational YangMing University Institute of NeuroscienceNational Chengchi University Division of GastroenterologyDepartment of Internal MedicineKaohsiung Medical University Hospital Division of Internal MedicineKaohsiung Municipal Ta-Tung HospitalKaohsiung Medical University Center for Infectious Disease and Cancer ResearchKaohsiung Medical University 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2018年第6卷第12期

页      面：514-520页

核心收录：

学科分类：10[医学] 

主　　题：Helicobacter pylori Cytochrome P450 2C19 Interleukin-1β Hybrid therapy Rabeprazole 

摘      要：AIM To evaluate the impact of cytochrome P450 2C19(CYP2C19) and interleukin-1β(IL-1β) polymorphisms on the efficacy of Helicobacter pylori(H. pylori) eradication by using rabeprazole-based hybrid *** A total of 88 H. pylori-infected patients were recruited to receive 14-d of hybrid therapy from March 2013 to May 2014. Three patients were excluded from analysis because of incomplete compliance. Either a follow-up endoscopy or 13 C-urea test was performed to determine the results of H. pylori eradication therapy. The genotypes of CYP2C19 and IL-1β were analyzed to investigate the impact on treatment effect. RESULTS The total eradication rate of H. pylori was 92.94%(79/85). According to the CYP2C19 genotypes, the rates of H. pylori eradication were 89.19% in extensive metabolizers(EM) and 95.83% in non-EM. The *** eradication rates regarding the IL-1β genotypes were 92.59% in the normal acid secretion group and 93.10% in the low acid secretion group. After multivariable logistic regression analysis, both the genotypes of CYP2C19 and IL-1β had no significant influences on the eradication rates of H. *** The CYP2C19 and IL-1β polymorphisms are not significantly independent factors of *** eradication using rabeprazole-based hybrid therapy.